HPLC法测定人脑脊液中万古霉素浓度的不确定度评定
|
摘要
目的:评定高效液相色谱法(HPLC)测定人脑脊液中万古霉素(vancomycin,VCM)浓度的不确定度。方法:分析并评定HPLC法测定人脑脊液中VCM浓度过程中的不确定度来源并进行合成。结果:人脑脊液中VCM低浓度(13.2μg·m L~(-1))和高浓度(438μg·m L~(-1))的扩展不确定度分别为1.03和22.0μg·m L~(-1)(P=95%,k=2)。结论:HPLC法测定人脑脊液中VCM浓度的不确定度在低浓度时主要由回收率、基质效应和生物样品配制引入,在高浓度时主要由基质效应、生物样品配制和重复性引入。
Objective: To evaluate the uncertainty of the determination of vancomycin in human cerebrospinal fluid by HPLC. Methods: The sources of uncertainty of the determination of vancomycin were analyzed and the uncertainty were evaluated and combined. Results: The expanded uncertainty of vancomycin at low( 13. 2 μg·m L- 1) and high( 438 μg·m L- 1) concentrations were 1. 03 and 22. 0 μg·m L- 1,respectively( P = 95%,k = 2).Conclusion: The uncertainty of the determination of vancomycin in human cerebrospinal fluid by HPLC is mainly caused by recovery,matrix effect,and sample preparation for low concentrations,and by the matrix effect,sample preparation,and repeatability for high concentrations.
Objective: To evaluate the uncertainty of the determination of vancomycin in human cerebrospinal fluid by HPLC. Methods: The sources of uncertainty of the determination of vancomycin were analyzed and the uncertainty were evaluated and combined. Results: The expanded uncertainty of vancomycin at low( 13. 2 μg·m L- 1) and high( 438 μg·m L- 1) concentrations were 1. 03 and 22. 0 μg·m L- 1,respectively( P = 95%,k = 2).Conclusion: The uncertainty of the determination of vancomycin in human cerebrospinal fluid by HPLC is mainly caused by recovery,matrix effect,and sample preparation for low concentrations,and by the matrix effect,sample preparation,and repeatability for high concentrations.
引文
[1]RYBAK MJ.The pharmacokinetic and pharmacodynamic properties of vancomycin[J].Clin Infect Dis,2006,42(Suppl 1):S35-S39.
[2]孙文斌,董吉荣,王玉海,等.万古霉素不同给药途径预防脑外伤颅内感染研究[J].南通医学院学报,2009,29(3):178-180.
[3]JJF1059.1-2012.测量不确定度评定与表示[S].2012.
[4]CNAS-CL01.检测和校准实验室能力认可准则[S].2006.
[5]王佳庆,朱乐亭,杨莉,等.HPLC法测定血浆中万古霉素浓度的不确定度评定[J].药品评价,2013,10(20):31-35.
[6]杨瑞,董晓茜,唐思,等.LC-MS法测定人血浆中五味子醇甲的不确定度评定[J].药物评价研究,2015,38(1):61-65.
[7]王猛猛,贺敏,过林,等.LC-MS/MS法测定人血浆中吡啡尼酮的浓度及其方法不确定度评定[J].中国药房,2015,26(8):1056-1059.
[8]梅升辉,冯卫星,朱乐亭,等.HPLC-MS/MS法测定人脑脊液中替加环素浓度的不确定度评定[J].中南药学,2015,13(7):693-697.
[9]梅升辉,冯卫星,朱乐亭,等.LC-MS/MS法测定人血浆中氯吡格雷活性代谢物衍生物浓度的不确定度评定[J].中国药房,2015,26(23):3206-3209.
[10]过林,裘福荣,王猛猛,等.LC-MS/MS法测定人血浆中双氯芬酸浓度的不确定度评定[J].安徽医药,2015,19(4):627-631.
[11]严蓓,曹国颖,闫记灵,等.LC-MS/MS法测定人血浆和尿中匹诺塞林浓度的不确定度评定及对比分析[J].药物分析杂志,2014,34(7):1216-1222.
[12]齐会红,李扬,史爱欣,等.HPLC-MS/MS法测定人血浆中马来酸甲麦角新碱浓度的不确定度评价[J].中国新药杂志,2014,23(10):1127-1132.
[13]严蓓,曹国颖,闫记灵,等.高效液相色谱质谱联用法测定人粪便中匹诺塞林浓度的不确定度评定[J].临床药物治疗杂志,2014,12(2):35-39.
[2]孙文斌,董吉荣,王玉海,等.万古霉素不同给药途径预防脑外伤颅内感染研究[J].南通医学院学报,2009,29(3):178-180.
[3]JJF1059.1-2012.测量不确定度评定与表示[S].2012.
[4]CNAS-CL01.检测和校准实验室能力认可准则[S].2006.
[5]王佳庆,朱乐亭,杨莉,等.HPLC法测定血浆中万古霉素浓度的不确定度评定[J].药品评价,2013,10(20):31-35.
[6]杨瑞,董晓茜,唐思,等.LC-MS法测定人血浆中五味子醇甲的不确定度评定[J].药物评价研究,2015,38(1):61-65.
[7]王猛猛,贺敏,过林,等.LC-MS/MS法测定人血浆中吡啡尼酮的浓度及其方法不确定度评定[J].中国药房,2015,26(8):1056-1059.
[8]梅升辉,冯卫星,朱乐亭,等.HPLC-MS/MS法测定人脑脊液中替加环素浓度的不确定度评定[J].中南药学,2015,13(7):693-697.
[9]梅升辉,冯卫星,朱乐亭,等.LC-MS/MS法测定人血浆中氯吡格雷活性代谢物衍生物浓度的不确定度评定[J].中国药房,2015,26(23):3206-3209.
[10]过林,裘福荣,王猛猛,等.LC-MS/MS法测定人血浆中双氯芬酸浓度的不确定度评定[J].安徽医药,2015,19(4):627-631.
[11]严蓓,曹国颖,闫记灵,等.LC-MS/MS法测定人血浆和尿中匹诺塞林浓度的不确定度评定及对比分析[J].药物分析杂志,2014,34(7):1216-1222.
[12]齐会红,李扬,史爱欣,等.HPLC-MS/MS法测定人血浆中马来酸甲麦角新碱浓度的不确定度评价[J].中国新药杂志,2014,23(10):1127-1132.
[13]严蓓,曹国颖,闫记灵,等.高效液相色谱质谱联用法测定人粪便中匹诺塞林浓度的不确定度评定[J].临床药物治疗杂志,2014,12(2):35-39.